These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31234489)

  • 1. Paraoxonase 1, HDL Subclasses and Post Surgery Acute Inflammation: A Pilot Study.
    Bains Y; Caccavello R; Kotani K; Gugliucci A
    Antioxidants (Basel); 2019 Jun; 8(6):. PubMed ID: 31234489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraoxonase 1 lactonase activity and distribution in the HDL subclasses in the cord blood.
    Gugliucci A; Numaguchi M; Caccavello R; Kimura S
    Redox Rep; 2014 May; 19(3):124-32. PubMed ID: 24620935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo.
    Gugliucci A
    Clin Chim Acta; 2014 Feb; 429():38-45. PubMed ID: 24280342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL.
    Gugliucci A; Kinugasa E; Ogata H; Caccavello R; Kimura S
    Clin Chim Acta; 2014 Mar; 430():9-14. PubMed ID: 24384301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paraoxonase 1 and HDL maturation.
    Gugliucci A; Menini T
    Clin Chim Acta; 2015 Jan; 439():5-13. PubMed ID: 25261854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence.
    Bobin-Dubigeon C; Lefrançois A; Classe JM; Joalland MP; Bard JM
    Clin Biochem; 2015 Nov; 48(16-17):1181-3. PubMed ID: 26188919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I.
    Gaidukov L; Tawfik DS
    Biochemistry; 2005 Sep; 44(35):11843-54. PubMed ID: 16128586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes.
    Passaro A; Vigna GB; Romani A; Sanz JM; Cavicchio C; Bonaccorsi G; Valacchi G; Cervellati C
    Oxid Med Cell Longev; 2018; 2018():1752940. PubMed ID: 30524650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of paraoxonase 1 (PON1) on HDL
    Miljkovic M; Stefanovic A; Vekic J; Zeljkovic A; Gojkovic T; Simic-Ogrizovic S; Bogavac-Stanojevic N; Cerne D; Ilic J; Stefanovic I; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Kotur-Stevuljevic J
    Clin Biochem; 2018 Sep; 60():52-58. PubMed ID: 30130521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Arylesterase, Paraoxonase, and Lactonase Activities and Paraoxonase-1 Concentrations in Morbidly Obese Patients and Their Relationship with Non-Alcoholic Steatohepatitis.
    Castañé H; Jiménez-Franco A; Martínez-Navidad C; Placed-Gallego C; Cambra-Cortés V; Perta AM; París M; Castillo DD; Arenas M; Camps J; Joven J
    Antioxidants (Basel); 2023 Nov; 12(12):. PubMed ID: 38136158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Amyloid A, Paraoxonase-1 Activity, and Apolipoprotein Concentrations as Biomarkers of Subclinical Atherosclerosis Risk in Adrenal Incidentaloma Patients.
    Imga NN; Topcuoglu C; Berker D; Turhan T
    Arch Med Res; 2018 Apr; 49(3):182-190. PubMed ID: 30031631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of serum amyloid A and oxidative stress with paraoxonase 1 in sarcoidosis patients.
    Ivanišević J; Kotur-Stevuljević J; Stefanović A; Spasić S; Vučinić Mihailović V; Videnović Ivanov J; Jelić-Ivanović Z
    Eur J Clin Invest; 2016 May; 46(5):418-24. PubMed ID: 26919159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraoxonase, arylesterase and lactonase activities of paraoxonase-1 (PON1) in obese and severely obese women.
    Cervellati C; Bonaccorsi G; Trentini A; Valacchi G; Sanz JM; Squerzanti M; Spagnolo M; Massari L; Crivellari I; Greco P; Parladori R; Passaro A; Ricci G
    Scand J Clin Lab Invest; 2018; 78(1-2):18-24. PubMed ID: 29168398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I.
    Gaidukov L; Viji RI; Yacobson S; Rosenblat M; Aviram M; Tawfik DS
    Biochemistry; 2010 Jan; 49(3):532-8. PubMed ID: 20025294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High density lipoprotein subfractions and paraoxonase 1 in children.
    Muchová J; Andrezálová L; Oravec S; Nagyová Z; Garaiova I; Ďuračková Z
    Acta Biochim Pol; 2016; 63(3):555-63. PubMed ID: 27262841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paraoxonase 1 and HDL subfractions in hypercholesterolemic children and adolescents.
    Duracková Z; Muchová J; Andrezálová L; Oravec S; Nagyová Z; Garaiova I
    Free Radic Biol Med; 2014 Oct; 75 Suppl 1():S29. PubMed ID: 26461330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.
    Sorenson RC; Bisgaier CL; Aviram M; Hsu C; Billecke S; La Du BN
    Arterioscler Thromb Vasc Biol; 1999 Sep; 19(9):2214-25. PubMed ID: 10479665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
    Chait A; Han CY; Oram JF; Heinecke JW
    J Lipid Res; 2005 Mar; 46(3):389-403. PubMed ID: 15722558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low protective PON1 lactonase activity in an Arab population with high rates of coronary heart disease and diabetes.
    Gugliucci A; Caccavello R; Nassar H; Abu Ahmad W; Sinnreich R; Kark JD
    Clin Chim Acta; 2015 May; 445():41-7. PubMed ID: 25801214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity.
    Kjellmo CA; Karlsson H; Nestvold TK; Ljunggren S; Cederbrant K; Marcusson-Ståhl M; Mathisen M; Lappegård KT; Hovland A
    J Clin Lipidol; 2018; 12(1):193-202. PubMed ID: 29146227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.